Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study ; volume:22 ; number:1 ; day:27 ; month:10 ; year:2020 ; pages:1-11 ; date:12.2020
Breast cancer research ; 22, Heft 1 (27.10.2020), 1-11, 12.2020
- Urheber
-
O’Shaughnessy, Joyce
Brezden-Masley, Christine
Cazzaniga, Marina
Dalvi, Tapashi
Walker, Graham
Bennett, James
Ohsumi, Shozo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13058-020-01349-9
- URN
-
urn:nbn:de:101:1-2020121118475952484618
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 05:24 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- O’Shaughnessy, Joyce
- Brezden-Masley, Christine
- Cazzaniga, Marina
- Dalvi, Tapashi
- Walker, Graham
- Bennett, James
- Ohsumi, Shozo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study
BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study
BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study
BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer